pentetate zinc trisodium
PENTETATE ZINC TRISODIUM (pentetate zinc trisodium) is zn-dtpa forms stable chelates with metal ions by exchanging zinc for a metal of greater binding capacity. Approved for individuals with known, suspected internal contamination with plutonium, americium and 1 more indications. First approved in 2004.
Drug data last refreshed 15h ago · AI intelligence enriched 2mo ago
Pentetate Zinc Trisodium (Zn-DTPA) is a chelating agent that forms stable complexes with radioactive metal ions (plutonium, americium, curium) and promotes their urinary excretion. Administered via inhalation or intravenous injection, it is indicated for individuals with known or suspected internal contamination with these actinide elements to increase elimination rates. The zinc component exchanges with the radioactive metal, forming chelate complexes that are then cleared by glomerular filtration.
This niche product approaching LOE indicates a small, specialized commercial team with limited growth prospects and likely consolidation or deprioritization ahead.
Zn-DTPA forms stable chelates with metal ions by exchanging zinc for a metal of greater binding capacity. The radioactive chelates are then excreted by glomerular filtration into the urine. In animal studies, Zn-DTPA forms less stable chelates with uranium and neptunium in vivo resulting in…
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
This ultra-niche product with zero linked jobs offers limited career growth and primarily attracts specialists in nuclear/radiological emergency response and government affairs. Professionals joining this team should expect a small, stable group focused on compliance and emergency preparedness rather than commercial expansion.